Brought to you by 
Raven Biotechnologies brings in $20.6mm from Series B financing
22 Mar 2002
Executive Summary
Raven Biotechnologies (monoclonal antibodies) grossed $20.6mm in its Series B round led by new investor US Venture Partners. Other participants were H&Q's Life Sciences Investors and Healthcare Investors Funds, also new, and existing investors CMEA Ventures, Viridian Capital, and some individuals.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Raven Biotechnologies brings in $20.6mm from Series B financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice